|
Active substance |
olaparib |
|
Holder |
AstraZeneca |
|
Status |
Closed |
|
Indication |
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. |
|
Public documents |
|
|
Last update |
12/05/2020 |
LYNPARZA
Last updated on 02/10/2024